Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. — CFSMEATLAS
E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedMachine draft
Standard · 3 min
Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents.
Rowe, K S · Journal of psychiatric research · 1997 · DOI
Quick Summary
This study tested whether intravenous gammaglobulin (a treatment containing antibodies from donated blood) could help adolescents with ME/CFS. Seventy teenagers received either the real treatment or a placebo (fake treatment) given as three infusions over three months. Both groups showed improvement in their ability to attend school and participate in activities by six months, but the study could not prove the real treatment worked better than placebo.
Why It Matters
This study addresses whether immune-modulating therapy might benefit adolescents with ME/CFS, a population often severely impacted. The rigorous double-blind design helps establish whether observed improvements are due to the treatment itself or other factors like natural recovery or placebo effect.
Observed Findings
Significant mean functional improvement was observed in the treatment group at six-month follow-up.
Both treatment and placebo groups showed significant improvement from baseline to six months.
Adverse effects were common in both the active treatment and placebo groups.
Adverse effects were not predictive of treatment response.
Blinding was successful; recipients could not identify which solution they received.
Inferred Conclusions
Intravenous gammaglobulin did not demonstrate superiority over placebo in improving function in adolescents with ME/CFS.
The substantial improvement in both groups suggests either a strong placebo effect, natural recovery trajectory, or non-specific benefits of participation in a structured trial.
Adverse effects occur with both active and placebo solutions and are not useful markers of treatment efficacy.
Remaining Questions
Does intravenous gammaglobulin benefit specific ME/CFS subgroups (e.g., those with immune dysregulation markers) not identified in this broader trial?
What mechanism drove the improvement in the placebo group, and can this be harnessed therapeutically?
What This Study Does Not Prove
This study does not prove that intravenous gammaglobulin is ineffective for ME/CFS, as both groups improved substantially; it demonstrates no superiority over placebo. The study cannot determine whether observed improvements reflect natural disease course, placebo response, or effects unrelated to the immune mechanism being targeted. Longer-term follow-up and larger samples would be needed to definitively rule out benefit in specific subgroups.
Tags
Symptom:Fatigue
Phenotype:Pediatric
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →